PSMA antibody
-
- Target See all PSMA (FOLH1) Antibodies
- PSMA (FOLH1) (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1 (FOLH1))
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This PSMA antibody is un-conjugated
-
Application
- ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))
- Specificity
- 107.1A4 recognizes an antigen, which appeared to be distinct from those previously described and shows specific tumor targeting in preliminary in vivo studies. MAb 107-1A4 is suggested to recognize a distinct conformational and unique epitope in the extracellular domain of PSMA. PSMA is a type II membrane glycoprotein of 100kDa that has a short intracellular N-terminal domain (residues 1 to 18), a transmembrane region (residues 19 to 43) and a large extracellular domain consisting of residues 44 to 750.
- Characteristics
- Membrane,Tumour marker
- Purification
- Supernatant
- Clone
- 107-1A4
- Isotype
- IgG1
- Top Product
- Discover our top product FOLH1 Primary Antibody
-
-
- Application Notes
- MAb 107-1A4 could not be used in Western blot, is useful for immunohistochemistry on frozen and paraffin-embedded tissues, immunocytochemistry, flow cytometry and ELISA. Optimal antibody dilution should be determined by titration, recommended range is 1:100 – 1:1000 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent.
- Comment
-
107.1A4 is a mouse monoclonal IgG1/k antibody derived by fusion of SP2/0-Ag14 mouse myeloma cells with spleen cells from an immunized mouse, using a two-phase immunization protocol involving the prostate cancer cell line LNCaP.
- Restrictions
- For Research Use only
-
- Buffer
- 0.09% sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
-
-
A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts." in: Prostate cancer and prostatic diseases, Vol. 1, Issue 4, pp. 208-215, (2002) (PubMed).
: "Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology." in: International journal of cancer. Journal international du cancer, Vol. 92, Issue 6, pp. 871-6, (2001) (PubMed).
: "
-
A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts." in: Prostate cancer and prostatic diseases, Vol. 1, Issue 4, pp. 208-215, (2002) (PubMed).
-
- Target
- PSMA (FOLH1) (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1 (FOLH1))
- Alternative Name
- PSMA (FOLH1 Products)
- Synonyms
- FGCP antibody, FOLH antibody, GCP2 antibody, GCPII antibody, NAALAD1 antibody, NAALAdase antibody, PSM antibody, PSMA antibody, mGCP antibody, mopsm antibody, Naalad antibody, putative N-acetylated-alpha-linked acidic dipeptidase antibody, folate hydrolase 1B antibody, folate hydrolase 1 antibody, folate hydrolase (prostate-specific membrane antigen) 1 antibody, LOC451185 antibody, FOLH1B antibody, FOLH1 antibody, Folh1 antibody
- Background
- Prostate specific antigen (PSA) is the most widely used marker of prostate cancer. Immunoassays for PSA using monoclonal (MAb) or polyclonal antibodies have clinical applications, such as monitoring and early detection of prostate cancer. However, PSA is not a perfect tumor marker because serum levels often are elevated in men with benign prostatic hyperplasia, prostatitis and other nonmalignant disorders and also because levels are not always elevated in individuals with early prostate cancer. 107-1A4 is a new prostate cancer-reactive MAb which can identify additional proteins that could be of value for the diagnosis and treatment of prostate cancer. It shows selective reactivity to prostate epithelial membrane antigens.
-